Yard Force Robotic Mowers Have Obtained "Green Product" Mark by TÜV
31.1.2023 14:20:00 EET | Business Wire | Press release
Yard Force, a leading manufacturer of innovative outdoor power equipment, has announced the launch of its MB400 and MB800 robotic mowers on the German market. These models come equipped with Bluetooth and app control, providing users with convenient and easy access to their mowers from their smartphones or tablets.
In addition to their advanced technology features, both the Yard Force MB400 and MB800 come with a unique feature that allows for decking to be cleaned using water. This innovative feature not only makes cleaning the decking easier, but also helps to prevent the build-up of algae and other contaminants that can affect the appearance and longevity of the decking.
The Yard Force MB400 and MB800 are also equipped with a free garage, providing users with a convenient and secure storage solution for their mowers. This is particularly useful for those who wish the robotic mower could find shelter during rain or snow and use the robotic mower for a longer life.
Yard Force launches the two new models on the 10th anniversary of its robotic mowers, setting the standard once again:
In addition to their impressive features, both the Yard Force MB400 and MB800 have been awarded the "Green Product" certification by TÜV, a leading certification organizaition for environmental, social, and governance (ESG) standards. This certification recognizes the mowers' eco-friendly design and technology, making them a smart and sustainable choice for homeowners looking to reduce their carbon footprint.
In 2013, the company started selling its robotic mowers in Germany and has since equipped tens of thousands of German gardens with the innovative and practical robotic mowers.
The new Yard Force MB400 and MB800 are designed to provide users with a convenient and efficient solution for maintaining their lawns. With maximum 400m2 and 800 m2 working area respectively, these mowers are perfect for small to medium sized lawns, and can easily navigate around obstacles such as trees and garden furniture.
The Bluetooth and app control features of the Yard Force MB400 and MB800 allow users to easily set up and customize their mowing schedule, as well as monitor the mower's performance and receive notifications on their smartphone or tablet. This level of control and convenience makes the MB400 and MB800 a popular choice for busy homeowners who want to maintain their lawns without the hassle of traditional mowing methods.
The decking cleaning feature of the Yard Force MB400 and MB800 is another standout feature that sets these mowers apart from their competitors. By using water to clean the decking, users can easily remove dirt and debris, ensuring that their decking stays looking clean and fresh all year round. This feature also helps to prevent the build-up of algae and other contaminants, which can damage the decking and reduce its lifespan.
Overall, the Yard Force MB400 and MB800 are a highly innovative and convenient solution for maintaining a healthy and well-groomed lawn. With their advanced technology, eco-friendly design, and unique decking cleaning feature, these mowers are sure to be a hit with German homeowners looking for a more efficient and sustainable way to care for their lawns.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005560/en/
Contact information
Email: linyinlu@sumec.com.cn
Phone number: +86-13770517766
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom